Mason Street Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Mason Street Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-570,080	Closed	-$32.8M	–	1712
2014 Q4	$32.8M	Hold	570,080	–	–	0.23%	91
2014 Q3	$30.6M	Hold	570,080	–	–	0.24%	80
2014 Q2	$29.9M	Hold	570,080	–	–	0.23%	88
2014 Q1	$30.1M	Buy	+570,080	New	+$26.3M	0.24%	82

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

MIP

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Mason Street Advisors's TEVA Position: Q1 2015 in Review

Mason Street Advisors sold out of Teva Pharmaceuticals (TEVA) in Q1 2015, closing a stake of 570,080 shares — an estimated $32.8M sold.

Mason Street Advisors first reported a position in TEVA in Q1 2014 and held it in 4 quarters. The position peaked at $32.8M in Q4 2014. 822 funds tracked by Wall St. Rank hold TEVA as of Q1 2015.

Mason Street Advisors reported no remaining Teva Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
Mason Street Advisors sold 570,080 Teva Pharmaceuticals shares in Q1 2015, an estimated $32.8M.
Mason Street Advisors first reported a position in Teva Pharmaceuticals in Q1 2014 and held it in 4 quarters.
Mason Street Advisors's Teva Pharmaceuticals position peaked at $32.8M in Q4 2014.
822 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2015.

Based on Mason Street Advisors's 13F filing for Q1 2015, filed 15 May 2015.